clinical trial · NCT05120830

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

$NTLA →·phase2·active not recruiting·n = 37

Hereditary AngioedemaBiological NTLA-2002Normal Saline IV Administration

brief summary

This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).

started

Dec 10, 2021

primary completion

Apr 4, 2024

completion

Jul 1, 2026

last updated

Mar 24, 2026

official title

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol